Epidural Abscess Treatment Market size is expected to cross USD 81 billion by the end of 2035, growing at a CAGR of 9% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of epidural abscess treatment was over USD 38 billion. The growth of the market can be attributed to the increasing stances of epidural abscesses throughout the world. For instance, in 2022, around 0.7 to 1.8 cases of spinal epidural abscesses were reported for every 10,000 hospital admissions across the globe. Furthermore, the rapid increase in medical research and development activities and the significant rise in the aged populace are also estimated to drive market growth over the forecast period.
In addition to these, factors that are believed to fuel the market growth of epidural abscess treatment include the worldwide expansion in spinal surgeries. For instance, globally approximately 350 million spinal surgeries were performed in 2022. In addition to this, rising risks of infection caused by back and head surgeries are also estimated to boost the market growth in the coming years. Besides this, the surging cases of chronic ear infections are also anticipated to fuel the market growth as the such infection starts with swelling, severe pain, or an infection behind the eardrum which can permanently damage the eardrum.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~9% |
|
Base Year Market Size (2022) |
~ USD 38 Billion |
|
Forecast Year Market Size (2035) |
~ USD 81 Billion |
|
Regional Scope |
|
Growth Drivers
Challenges
End-user (Hospital, Pharmacy, Specialty Clinics)
The global epidural abscess treatment market is segmented and analyzed for demand and supply by end-user into hospital, pharmacy, specialty clinics, and others. Out of these four types of segments, the hospital segment is estimated to gain the largest market share of about ~41% in the year 2035. The growth of the segment can be attributed to the increasing healthcare expenditure, followed by the surging cases of epidural abscess, and the surging ratio of people who require immediate treatment for this condition. For instance, in 2021, an increase of approximately 2% to 5% was reported in intracranial epidural abscess (IEAs) cases throughout the world. In addition to this, an expansion in awareness about epidural abscesses in developed countries is also estimated to propel the segment growth in the projected time frame.
Treatment (Antifungal Drugs, Antibiotics, Surgery)
The global epidural abscess treatment market is also segmented and analyzed for demand and supply by treatment into antifungal drugs, antibiotics, and surgery. Amongst these three segments, the surgery segment is expected to garner a significant share of around ~75% in the year 2035. The growth of the segment can be credited to the rising patient pool with spinal epidural abscesses (SEAs), which mostly seek surgical treatment for a better cure of the such condition. Moreover, the higher efficacy of surgical procedures including decompressions, and open or minimally invasive procedures to treat the spinal epidural abscess is also anticipated to drive the segment growth over the projected time frame. On the other hand, the antibiotics segment is projected to witness a massive CAGR during the forecast period, owing to the rising usage of antibiotics in the effective treatment of epidural abscesses in conjunction with surgical procedures. The normal duration of antibiotic treatment is nearly 3 to 4 weeks to treat a patient with an epidural abscess. Besides this, some spinal epidural abscesses can be treated by only giving a dose of antibiotics for around 4-6 weeks.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment |
|
|
By End-User |
|
North American Market Forecast
The market share of epidural abscess treatment in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~38% by the end of 2035. The growth of the market can be attributed majorly to the high healthcare expenditure, followed by the rising frequency of epidural abscess cases in the region. According to the Centers for Medicare and Medicaid Services (CMS), healthcare expenditure in the United States expanded by 2.7% to USD 4.3 trillion in 2021. This healthcare investment accounted for 18.3% of the nation's GDP. In addition to this, rising awareness in people regarding the epidural abscess, coupled with the surge in early detection and treatment for such conditions is also anticipated to accelerate the market growth further over the forecast period in the region. Moreover, the increasing ratio of people who inject drugs is also projected to drive market growth further in the region.
APAC Market Statistics
The Asia Pacific epidural abscess treatment market is estimated to be the second largest, registering a share of about ~27% by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of infection cases owing to the surge in the geriatric population, as their immunity is compromised. Based on the World Bank statistics, the population above 65 years of age in India expanded by 90,719,952 in 2020, while, it expanded by 167,808,567 in China. Moreover, rising investment in R&D activities and improving medical facilities are estimated to boost market growth. In addition to this, a notable increase in head and spinal surgeries is also estimated to boost the market growth in the APAC region over the projected time frame.
Europe Market Forecast
Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share of about ~20% by the end of 2035. The growth of the market can be attributed majorly to the expanding stances of head surgeries, coupled with the significant expansion in traumatic brain injury (TBI) cases, coupled with the surge in research and development activities. Moreover, the radically increasing frequency of acute otitis media in younger people in Germany is also projected to drive the growth of the epidural abscess treatment market in the European region throughout the forecast period.
Sun Pharmaceutical Industries Limited has completed the acquisition of Concert Pharmaceuticals, Inc., which is a leading clinical biopharmaceutical company.
Sandoz Inc. introduced Ciprofloxacin 0.3% + Dexamethasone 0.1% otic suspension in the United States for the treatment of bacterial infections such as acute otitis media and acute otitis externa.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?